Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection

Annals of Internal Medicine

Volumn 131, Issue 9, 1999, Pages 696-701

  Baffis, Vicky ^a,c   Shrier, Lan ^a   Sherker, Averell H ^a   Szilagyi, Andrew ^a,b   Hudson, Barbara ^b  

^a MCGILL UNIVERSITY   (Canada)

^b Montreal General Hospital ^*

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOTHERAPY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032754340     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-131-9-199911020-00011     Document Type: Article

References (37)

1. Lai CL, Wu PC. Lok AS. Lin HJ. Ngan H, Lau JY, et al. Recombinant alpha 2 Interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Er J Cancer. 1989;60:928-33.
2. Collooni M. Buzzoni R, Bajetta E. Bochicchio AM, Bartoli C, Audisio R, et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer. 1993;72:3196-201.
3. Lin HJ, Lai CL. Wu PC. Serum hepatitis 8 viral DMA in HBsAg-positive hepatocellular carcinoma treated with Interferon or adriamycin. Br J Cancer. 1986:54:67-73.
4. Perrillo R. Interferon in the management of chronic hepatitis B. Dig Dis Sei. 1993:38:577-93.
5. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S. et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995:346:1051-5.
6. Valla DC. Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 1999:29:1870-5.
7. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCVrelated liver cirrhosis. J Hepatol. 1996;24:141-7.
8. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1997;27:201-5.
9. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 1997:25:754-8.
10. Serfaty L, Aumaître H, Chazouillères O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998;27:1435-40.
11. Effect of interferon-ot on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet. 1998:351:1535-9.
12. Don CI. Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol. 1992:31(Suppl):S137-42.
13. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Fukuda M, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer. 1998:82:827-35.
14. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology. 1997:26:1338-42.
15. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S. Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med. 1998:129:94-9.
16. Harper SE, Dienstag JL. Can interferon alfa treatment prevent hepatocellular carcinoma in patients with chronic hepatitis C infection and compensated cirrhosis? Hepatology. 1996:23:930-3.
17. Grimm I, Shaheen N. Can interferon prevent hepatocellular carcinoma in hepatitis C virus-induced cirrhosis? Gastroenterology. 1996:110:2019-21.
18. Andreone P, Cursaro C, Gramenzi A, Trevisani F, Gasbarrini G, Bernardi M. Interferon and hepatocellular carcinoma [Letter]. Lancet. 1996:347: 195.
19. Koretz RL Interferon and hepatocellular carcinoma (Letter). Lancet. 1996; 347:194-5.
20. Wong DK, Cheung AM, O'Rourke K, Naylor CD. Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigenpositive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993; 119:312-23.
21. Niederau C, Heintges T. Lange S. Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with Interferon alfa for chronic hepatitis B. N Engl J Med. 1996:334:1422-7.
22. Lin SM, Sheen IS. Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of Interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971-5.
23. Pilot HC. Hepatocyte death in hepatocarcinogenesis. Hepatology. 199S;28: 1-5.
24. Sherker AH, Marion PL Hepadnaviruses and hepatocellular carcinoma. Ann Rev Microbiol. 1991;45:475-507.
25. Szilagyi A, Alpert L Clinical and histopathological variation in hepatocellular carcinoma. Am J Gastroenterol. 1995:90:15-23.
26. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998:28:1687-95.
27. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashik K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065-7.
28. Marcellin P, Boyer N, Gervais A, Martinet M, Pouteau M, Costelnau C, et al. Long-term histologie improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997;127:875-81.
29. Poynard T, Bedossa P. Chevallier M, Mathurin P, Lemonnier C Trepo C, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med. 1995:332:1457-62.
30. Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by metaanalysis. J Hepatol. 1997;26:1187-99.
31. Camma C, Giunta M, Pinzello G, Morabito A, Verderio P, Pagliaro L Chronic hepatitis C and interferon alpha: conventional and cumulative metaanalyses of randomized controlled trials. Am J Gastroenterol. 1999;94:581-95.
32. McHutchison JG, Gordon SC. Schiff ER, Shiftman ML Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998:339:1485-92.
33. Fattovich G. Giustina G, Degos F, Tremolada F. Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997:112:463-72.
34. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988:318:1728-33.
35. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999:340:745-50.
36. Di Bisceglie AM, Carithers RL Jr, Gores GJ. Hepatocellular carcinoma. Hepatology. 1998:28:1161-5.
37. Everson GT, Jensen DM, Craig JR, van Leeuwen DJ, Bain VG, Ehrinpreis MN, et al. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics. Hepatology. 1999:30:271-6.